Study of the Angiogenesis by PET/CT in Patients With Lymphoma (RGDLymphome)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02490891|
Recruitment Status : Unknown
Verified July 2017 by Centre Henri Becquerel.
Recruitment status was: Recruiting
First Posted : July 7, 2015
Last Update Posted : July 11, 2018
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma||Device: RGD K5 PET scan||Phase 2|
After inclusion PET scans with FDG tracer and with a specific tracer of angiogenesis will be performed on patient with lymphoma. After two cycles of chemotherapy PET scans with the same tracers will be performed.
Overall survival and disease free survival will be monitored during 18 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of the Angiogenesis Measured by PET/CT With 18F-RGD-K5 in Patients With Lymphoma : a Preliminary Study|
|Actual Study Start Date :||November 2015|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||May 2020|
Experimental: PET scan with RGD K5 imaging
PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
Device: RGD K5 PET scan
PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
- Measure of angiogenesis with RGD K5 PET scan [ Time Frame: 3 months ]Measure of fixation, metabolic volume and angiogenic volume with RGD K5 traver
- Measure of angiogenic volume with K5 tracer [ Time Frame: 3 months ]Measure of SUV max, SUV peak, SUV mean, metabolic volume and angiogenic volume to determine angiogenesis parameters with RGD-K5 PET scansand correlation with results of anatomopathology.
- Overall survival [ Time Frame: 18 months ]Time between inclusion and death whatever the cause
- Disease-free survival [ Time Frame: 18 months ]Time between inclusion and progression or death
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02490891
|Contact: Pierre Vera, MD, PhDfirstname.lastname@example.org|
|Contact: Doriane Richard, PhDemail@example.com|
|Centre Henri Becquerel||Recruiting|
|Rouen, France, 76038|
|Contact: Pierre Vera, MD,PhD +33232082255 firstname.lastname@example.org|
|Principal Investigator:||Pierre Vera, MD, PhD||Centre Henri Becquerel|